drugset / Trial / NCT02232542

Tolerability and Safety of Duloxetine BID in Healthy Female Subjects

NCT02232542

Phase 1 Completed 32 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to assess the safety and tolerability of 100 mg of duloxetine BID compared to 40 mg of duloxetine BID or placebo for 7 days

Timeline

Start
2003-06
Primary completion
2003-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Duloxetine Small molecule 40 mg
Subject Duloxetine Small molecule 100 mg

Indications

No indication recorded.